FIELD: medicine.
SUBSTANCE: group of inventions relates to the treatment of a disorder of the central nervous system. A composition for the treatment of a disorder of the central nervous system (CNS) includes a benzoate compound and tannic acid or its pharmaceutically acceptable salt, where the benzoate compound is sodium benzoate or lithium benzoate, where therapeutically effective amount of the benzoate compound is from 100 to 1200 mg in a composition, and where the benzoate compound and tannic acid are in a ratio from 60:1 to 3:1 by weight in a composition. A method for the treatment of a disorder of the central nervous system (CNS) in a patient is also disclosed.
EFFECT: group of inventions provides reduction in hyperactivity and restoration of sensory-motor deficit in a subject.
23 cl, 4 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS CONTAINING TANNIC ACIDS AND USE THEREOF | 2017 |
|
RU2715703C1 |
| D-AMINO ACID OXIDASE INHIBITORS AND THEIR THERAPEUTIC USE | 2018 |
|
RU2795513C2 |
| POLYMORPHOUS FORMS OF SODIUM BENZOATE AND THEIR USE | 2017 |
|
RU2782627C2 |
| SODIUM BENZOATE COCRYSTALS AND THEIR USE | 2017 |
|
RU2771810C2 |
| LITHIUM BENZOATE CO-CRYSTALS AND THEIR APPLICATIONS | 2017 |
|
RU2765625C2 |
| USE OF BENZOATE FOR TREATMENT OF DISORDERS OF CENTRAL NERVOUS SYSTEM | 2017 |
|
RU2780450C2 |
| POLYMORPHIC FORMS OF (2S)-(4E)-N-METHYL-5-[3-(5-ISOPROPOXYPYRIDIN)YL]-4-PENTEN-2-AMIN FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | 2007 |
|
RU2440984C2 |
| NEW 1,4-DIAZA-BICYCLO[3,2,2]NONYL-OXADIAZOLYL DERIVATIVES AND THEIR MEDICAL APPLICATION | 2007 |
|
RU2427581C2 |
| MATRIX TABLET WITH MODIFIED NERAMEXANE RELEASE | 2006 |
|
RU2422135C2 |
| COMPOSITIONS AND METHODS ASSOCIATED THEREWITH | 2017 |
|
RU2764716C2 |
